 |
 |
PharmaVOICE - June 2009 “Obamaceuticals:” The Good, The Bad, The Controversial, and the Undecided By Robin Robinson According to the Deloitte 2009 Industry Outlook report published in December 2008, the Obama Administration could make more changes to the nation’s healthcare system than have occurred since the 1960s. While there are many government policy changes proposed, PharmaVOICE asked leaders from all segments of the industry to share their opinions on only a few of the more pertinent at this time. It has been reported that President Obama expects to see a healthcare bill on his desk before the end of 2009, and the issue most likely to be addressed first in that bill is increased insurance access for the under- and uninsured. Sidebars Corporate tax benefit deferral will occur later rather than sooner Obamaceuticals: A Guide to Reform Experts on this Topic Susan Dorfman. VP Global Marketing, Skila, which develops knowledge-driven management solutions for the pharma industry. For more information, visit skila.com or e-mail susandorfman@skila.com. Peter Pitts. President, Center for Medicine in the Public Interest (CMPI), and Partner and Director of Porter Novelli’s global health practice; CMPI discusses, debates, and demonstrates how exponential and accelerating technological progress coupled with smart public policy will enhance and advance 21st century healthcare by predicting, preventing, diagnosing, and treating disease with greater speed, more precision, and less cost. For more information, visit cmpi.org. Michael Ruggiero. Senior Director, Government Policy and External Affairs, Astellas Pharma US, which is dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, visit us.astellas.com or e-mail michael.ruggiero@us.astellas.com. Kim Slocum. President, KDS Consulting LLC, an organization devoted to helping healthcare organizations understand the broader environment in which they operate and assisting them in finding strategic sustainable solutions. For more information, visit kimslocum.com or e-mail kdsconsulting@verizon.net. Billy Tauzin. President and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA), represents the country’s leading pharmaceutical research and biotech companies. For more information, visit phrma.org.
|
